🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Turkey / NCT07552350
Active, not recruiting Not applicable

Bioactive Restorative Materials for Class II Restorations

NCT07552350 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-02-14
Last updated
2026-04-27

Condition(s) studied

Bioactive Dental Restorative MaterialsClass II Dental Caries

Investigational drug(s) / intervention(s)

Giomer Restorative MaterialGiomer-Based Bulk-Fill Restorative MaterialResin-Modified Glass Ionomer Cement

Giomer Restorative Material: Class II posterior restorations restored with a giomer restorative material according to the manufacturer's instructions under standardized clinical conditions.

Giomer-Based Bulk-Fill Restorative Material: Class II posterior restorations restored with a giomer-based bulk-fill restorative material according to the manufacturer's instructions under standardized clinical conditions.

Resin-Modified Glass Ionomer Cement: Class II posterior restorations restored with a resin-modified glass ionomer cement according to the manufacturer's instructions under standardized clinical conditions.

Study summary

This randomized split-mouth clinical trial aims to evaluate the clinical performance of bioactive restorative materials used in Class II restorations in permanent posterior teeth. The study compares a giomer-based bulk-fill restorative material, a giomer restorative material, and a resin-modified glass ionomer cement in terms of clinical success and overall clinical performance. Patients requiring at least three Class II restorations in posterior teeth are treated under standardized clinical conditions. Clinical evaluations are performed at baseline and follow-up visits to assess short- and long-term outcomes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
50 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Healthy individuals without any systemic disease that could contraindicate restorative treatment 2. Individuals aged between 18 and 50 years 3. Individuals who agreed to participate in the study and signed the informed consent form 4. Individuals with at least three proximal carious lesions in premolar or molar teeth, classified as D2 (lesions extending to the middle third of dentin) or D3 (lesions extending to the inner third of dentin) according to the ICDAS classification 5. Teeth with intact enamel and dentin structure that had not been previously restored 6. Individuals who brushed their teeth at least twice a day 7. Individuals without physical disabilities that could prevent attendance at follow-up visits 8. Individuals with at least 20 teeth in occlusion and with antagonist teeth in the opposing arch 9. Vital teeth without signs of periapical pathology 10. Periodontally healthy teeth that were not used as abutments for any prosthetic restoration 11. Teeth without displacement or mobility 12. Individuals who had undergone initial periodontal therapy Exclusion Criteria: 1. Pregnant or breastfeeding individuals 2. Individuals with advanced periodontal disease 3. Individuals using removable partial dentures 4. Individuals with bruxism 5. Individuals with severe malocclusion 6. Individuals with known allergies to resin-based restorative materials or adhesive agents 7. Individuals with a history of allergy to local anesthetics or their administration 8. Individuals with latex allergy 9. Individuals with poor oral hygiene 10. Teeth that had been previously restored or were undergoing orthodontic treatment

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Hacettepe University Faculty of Dentistry, Department of Restorative Dentistry Ankara Turkey (Türkiye)

More Hacettepe University trials in Turkey

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07552350 on ClinicalTrials.gov ↗ ← All trials in Turkey